One-glance verdict
Not enough data
Fair value unavailable
Not enough cash-flow history to value this one with our method.
Fundamentals snapshot
DBV Technologies S.A.
DBVT · NCM · Healthcare · Biotechnology
Current price
$9.05
52-week range
$8.63 - $26.18
Market cap
$568.78M
Balance sheet
Healthy
-244.68x Concerning
Net cash $167.20M. Interest coverage shows how many times profit covers the interest bill.
What stands out
0 Rewards
1 Risk
0 rewards · 1 risks
View details ↓What this company does
DBV Technologies S.A.
DBV Technologies is developing a patch called Viaskin to help people with food allergies, like peanut or milk allergies, by exposing their bodies to small amounts of the allergen. The main way they make money is by getting their treatments approved and then selling them, which is still a ways off as they are in the testing phases of their products. This matters because if their allergy patches work and get approved, they could offer a new way to manage severe allergies for millions of people.
How the company got here
DBV Technologies was founded in 2002 with a mission to develop innovative treatments for food allergies. The company's journey has been largely defined by its focus on a specific technology platform designed to deliver immunotherapy through the skin. A significant milestone was the development and late-stage testing of its lead product candidate for peanut allergies, which aimed to desensitize patients to allergens without injections. While this product faced regulatory hurdles, the company has continued to explore its technology for other allergies and diagnostic tools, adapting its strategy based on clinical trial results and market feedback.
What it actually does
DBV Technologies is a biopharmaceutical company focused on creating treatments for allergies. Think of them as developing "patches" that help the body's immune system get used to certain foods it's allergic to, like peanuts or milk. Instead of shots, their approach uses a special patch applied to the skin. They are also working on diagnostic tools to help doctors identify allergies more easily. Their main goal is to improve the lives of people suffering from potentially severe allergic reactions.
Epicutaneous Immunotherapy (Viaskin Technology)
This is the core of DBV Technologies' business, centered around its Viaskin technology platform. This platform is used to develop epicutaneous immunotherapy (EPIT) products, which are essentially skin patches designed to treat food allergies. The idea is to deliver small amounts of the allergen through the skin to gradually build tolerance in the patient's immune system. The most advanced product using this technology is for peanut allergies, which has gone through late-stage clinical trials. The company is also exploring this technology for other food allergies, like cow's milk protein allergy.
Diagnostic Tools
Beyond treatments, DBV Technologies is also involved in developing diagnostic tools to help identify allergies. They have a collaboration to develop a ready-to-use patch test for diagnosing non-IgE mediated cow's milk protein allergy (CMPA) in infants and toddlers. This means they are creating ways for doctors to more accurately and quickly figure out if a child has a specific type of milk allergy, which can be challenging to diagnose.
What management is betting on now
DBV Technologies is currently focused on advancing its pipeline of epicutaneous immunotherapy products and diagnostic tools. A key priority is the continued development and potential regulatory approval of its peanut allergy patch, aiming to bring a new treatment option to patients. Management is also investing in exploring the Viaskin technology for other food allergies and expanding its diagnostic capabilities. The company's strategy hinges on demonstrating the safety and efficacy of its skin-based delivery system to address unmet needs in allergy treatment and diagnosis.
Price history
How the share price has moved
—
Loading price history…
Earnings history
Last 8 quarters — what happened
Click any quarter to read the call summary and what the numbers say.
FY2024 Q3
$-22.85M
FY2024 Q4
$-12.38M
FY2025 Q1
$-19.68M
FY2025 Q2
$-33.94M
FY2025 Q3
$-32.55M
FY2025 Q4
$-35.55M
FY2026 Q1
$-49.50M
FY2026 Q2
$-53.00M
Revenue
$700.00K
Net income
$-50.40M
Diluted EPS
-0.12
Operating cash flow
$-52.60M
Free cash flow
$-53.00M
Fetching…
Sources
Revenue
$900.00K
Net income
$-47.60M
Diluted EPS
-0.11
Operating cash flow
$-49.10M
Free cash flow
$-49.50M
Fetching…
Sources
Revenue
$644.00K
Net income
$-44.83M
Diluted EPS
-0.24
Operating cash flow
$-35.17M
Free cash flow
$-35.55M
Fetching…
Sources
Revenue
$2.77M
Net income
$-33.16M
Diluted EPS
-0.24
Operating cash flow
$-32.44M
Free cash flow
$-32.55M
Fetching…
Sources
Revenue
$1.47M
Net income
$-41.88M
Diluted EPS
-0.31
Operating cash flow
$-33.91M
Free cash flow
$-33.94M
Fetching…
Sources
Revenue
$753.00K
Net income
$-27.08M
Diluted EPS
-0.26
Operating cash flow
$-19.67M
Free cash flow
$-19.68M
Fetching…
Sources
Revenue
$511.00K
Net income
$-23.02M
Diluted EPS
-0.23
Operating cash flow
$-12.25M
Free cash flow
$-12.38M
Fetching…
Sources
Revenue
$1.07M
Net income
$-30.44M
Diluted EPS
-0.32
Operating cash flow
$-22.46M
Free cash flow
$-22.85M
Fetching…
Sources
Is it cheap or expensive?
Fair value — vs current price $9.05
We couldn't calculate a fair value right now.
Is it drowning in debt?
Healthy
Net cash $167.2M - more cash than debt. Interest coverage -244.7x.
Net debt
$-167.20M
Interest coverage
-244.68x
DBV Technologies S.A. is healthier than 0 of 1 peers on balance-sheet leverage.
Healthy
Worse cushion
Baseline
Better cushion
DBVT
BASELINE
DBV Technologies S.A.
Total debt $7.70M Interest coverage -244.68x This is the baseline the peer rows are being compared against.
What you should know
The case for and against DBVT
0 Rewards
1 Risk
Rewards
Risks
-
Return on equity was -142.7% last year — the company lost money on shareholders' equity.
The numbers
All the key metrics, grouped by purpose
Tap any ? icon to learn what it means.
Valuation
How expensive the stock looks
P/E (TTM)
—
Forward P/E
-18.63x
P/B
3.34x
P/S
112.94x
EV/EBITDA
-2.13x
PEG ratio
—
Profitability
How much profit each dollar creates
Gross margin
100.0%
Operating margin
-7,228.6%
Net margin
0.0%
ROE
-142.7%
ROA
-60.6%
Health
Liquidity and balance-sheet strength
Debt / equity
0.05x
Current ratio
3.72x
Quick ratio
3.54x
Total debt
$7.70M
Total cash
$174.90M
Growth
How the business has been compounding
Revenue TTM
$5.02M
Revenue 5Y CAGR
-0.3%
EPS TTM
-3.50
EPS 5Y CAGR
—
Cash flow
How much cash the business throws off
Operating CF TTM
$-169.31M
Free CF TTM
$-121.71M
FCF margin
-2,425.5%
Dividend
Shareholder payout
Yield
0.0%
Payout ratio
—
Last ex-div date
—